The diabetes drug semaglutide, also known as Ozempic, has a positive effect for patients with chronic kidney damage and obesity. They

The effect of tenofovir amibufenamide (TMF) on blood lipid profiles in patients with chronic hepatitis B (CHB) remains unclear. This study aimed to explore whether TMF affects blood lipids during 48 weeks in patients with CHB.

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by the misfolding and accumulation of the mutant variant of alpha-1 antitrypsin (AAT) within hepatocytes, which limits its access to the circulation and exposes the lungs to protease-mediated tissue damage.

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear.

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.

Despite significant advancements in cancer treatment, drug resistance remains a persistent challenge. Cancer cells can often develop resistance to treatments such as chemotherapy, radiotherapy, and immunotherapy, leading to reduced treatment efficacy.

Data regarding risk factors and long-term outcomes of U.S. patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) are limited.

Findings suggest gut microbiome dysbiosis may influence lumbar degenerative spondylolisthesis, impacting inflammation and pain management strategies.

Men who followed the plan were able to stop injecting themselves with insulin within a month of starting their fasting schedule, a study has claimed

New study shows time-restricted eating is effective for managing type 2 diabetes, offering a simple and achievable dietary approach.

Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant. The research will be presented at ASN Kidney Week 2024 October 23– 27.

A new study suggests that semaglutide, used for type 2 diabetes and weight loss under brand names like Wegovy and Ozempic, could also lower the risk of Alzheimer's disease.

Researchers use real-world data in the United States to evaluate the protective role of semaglutide against Alzherimer’s disease.